In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002

This publication has 9 references indexed in Scilit:

• Novel antibacterial agents for the treatment of serious Gram-positive infections
  Expert Opinion on Investigational Drugs, 2003
• Efflux-Mediated Resistance to Tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1
  Antimicrobial Agents and Chemotherapy, 2003
• In Vitro and In Vivo Activities of Tigecycline (GAR-936), Daptomycin, and Comparative Antimicrobial Agents against Glycopeptide-IntermediateStaphylococcus aureusand Other Resistant Gram-Positive Pathogens
  Antimicrobial Agents and Chemotherapy, 2002
• Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936)
  Journal of Antimicrobial Chemotherapy, 2002
• In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamases
  Diagnostic Microbiology and Infectious Disease, 2001
• Preclinical Pharmacology of GAR-936, a Novel Glycylcycline Antibacterial Agent
  Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2000
• Mutations in the Interdomain Loop Region of thetetA(A) Tetracycline Resistance Gene Increase Efflux of Minocycline and Glycylcyclines
  Microbial Drug Resistance, 2000
• Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates
  Diagnostic Microbiology and Infectious Disease, 2000
• In Vitro and In Vivo Antibacterial Activities of a Novel Glycylcycline, the 9- t -Butylglycylamido Derivative of Minocycline (GAR-936)
  Antimicrobial Agents and Chemotherapy, 1999